MASLD (formerly NAFLD) and its inflammatory subset MASH (formerly NASH) affect ~38% and ~5% of U.S. adults respectively. Until recently, there were no FDA-approved drugs for either. In March 2024 resmetirom (Rezdiffra) was approved for MASH. A second class has since arrived: the Wegovy (semaglutide 2.4 mg) injection now carries an FDA accelerated-approval indication for noncirrhotic MASH with moderate to advanced fibrosis (Wegovy label, revised June 2026).
What MASLD and MASH are
- MASLD (metabolic dysfunction-associated steatotic liver disease): liver steatosis (≥5% liver fat) in the setting of cardiometabolic risk factors, without significant alcohol intake.
- MASH: the inflammatory subset of MASLD, characterized by hepatocyte injury and inflammation. Progresses to fibrosis (F1–F4) and eventually cirrhosis.
- The 2023 nomenclature change from NAFLD/NASH to MASLD/MASH reflected the understanding that the disease is fundamentally metabolic, not "non-alcoholic."
SYNERGY-NASH — tirzepatide phase 2 trial
Loomba et al. (NEJM 2024) randomized 190 adults with biopsy-confirmed MASH and stage F2–F3 fibrosis to tirzepatide 5/10/15 mg vs placebo for 52 weeks.
| Endpoint at 52 weeks | 5 mg | 10 mg | 15 mg | Placebo |
|---|---|---|---|---|
| MASH resolution | 44% | 56% | 62% | 10% |
| Fibrosis improvement ≥1 stage | 55% | 51% | 51% | 30% |
| Body weight change | −10.7% | −13.3% | −15.6% | −0.8% |
This is the strongest MASH resolution effect ever reported in a randomized trial. Phase 3 program is enrolling.
ESSENCE — semaglutide phase 3 trial
Semaglutide 2.4 mg in MASH with stage F2–F3 fibrosis. Part 1 results at 72 weeks showed MASH resolution in about 62% with semaglutide vs about 34% with placebo, and fibrosis improvement in about 37% vs 22%. These results supported Wegovy's accelerated approval for MASH; the outcomes part of the trial continues.
Why GLP-1 may work in MASH
Multiple mechanisms beyond weight loss alone: improved insulin sensitivity (reduces hepatic lipogenesis), reduced systemic and hepatic inflammation, possible direct GLP-1 receptor effects in liver. The hepatic effect appears larger than would be predicted from weight loss alone, consistent with direct mechanism.
How to assess if you might have MASH
- Elevated ALT and AST with cardiometabolic risk factors (T2D, obesity, hypertension, dyslipidemia).
- FIB-4 score ≥1.3 (non-invasive risk stratification using age, AST, ALT, platelets).
- Elastography (FibroScan) for non-invasive fibrosis staging.
- Liver biopsy remains the gold standard for definitive MASH diagnosis and fibrosis staging.
What this means for compounded GLP-1 use
Use of compounded GLP-1 for off-label MASH-directed treatment is becoming more common in clinical practice, especially in patients with concurrent obesity and high FIB-4 scores. Considerations:
- Coordination with hepatology is reasonable for patients with confirmed F2–F3 fibrosis.
- Liver enzymes should be monitored at baseline and during therapy.
- Compounded semaglutide is made with the drug in Wegovy but is not the same product and has no FDA-approved MASH labeling. The Wegovy injection itself carries an FDA accelerated-approval indication for noncirrhotic MASH with moderate to advanced fibrosis (Wegovy label, revised June 2026).
- Patients with confirmed MASH and F2–F3 fibrosis now have two FDA-approved options, resmetirom (Rezdiffra) and the Wegovy injection; which fits is a decision for the treating clinician.
What to expect next
Tirzepatide has no MASH indication; its phase 3 program continues. People with fatty liver disease are not eligible for the Medicare GLP-1 Bridge, though a Part D plan might cover a GLP-1 for an approved indication. Patients currently being treated for MASLD/MASH should expect treatment options to expand.